INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR3m ago
SEC 13F3m ago
ROBINHOOD CHAIN2m ago
SEC FORM 4/Open-market saleVerified data

Poulton Jeffrey V. sold ALNY

EVP, Chief Financial Officer · ALNYLAM PHARMACEUTICALS, INC. · Common Stock

Side
SELL
Value
$28K
Shares
78
Price
$355.16
Executed
Jan 12, 2026
Disclosed
Jan 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 12 executedJan 14, 2026 disclosed

ALNY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
36/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $28K reported value · 0.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+15 / 15

    4 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALNY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$5,667
    15 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$96K
    269 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$6,676
    18 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$7,137
    19 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    16
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Grant or award
    		A—
    19.0K sh
    		Jan 11, 2026Jan 14, 2026
    traded Jan 11, 2026
    		+3dSEC FORM 4

    Evidence

    32
    GY
    Greenstreet YvonneDirector, Chief Executive Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$87K
    247 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$7,137
    19 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$15K
    40 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$5,242
    14 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$5,242
    14 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$31K
    85 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$18K
    50 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$80K
    220 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$73K
    199 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$35K
    98 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$73K
    199 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$17K
    47 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    GP
    Garg PushkalEVP Chief R&D
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$15K
    41 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$34K
    92 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    39
    TT
    Tanguler TolgaEVP, Chief Commercial Officer
    ALNYALNYLAM PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$80K
    220 sh
    		Jan 12, 2026Jan 14, 2026
    traded Jan 12, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001735276-26-000013
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 12, 2026
    Published
    Jan 14, 2026
    Ingested by INSIDER
    Nov 5, 04:22 UTC
    Last re-read
    Nov 5, 04:22 UTC

    Extracted facts

    Filer
    Poulton Jeffrey V.
    Role
    EVP, Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    ALNYLAM PHARMACEUTICALS, INC.
    Ticker
    ALNY
    Shares
    78
    Price per share
    $355.16
    Value
    $27,702
    Execution date (reported)
    Jan 12, 2026
    Owned after transaction
    60.1K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 78
    • Price: $355.16

    = $27,702

    What this establishes

    Poulton Jeffrey V. filed this Form 4 reporting a open-market sale of ALNY on Jan 12, 2026. It became public on Jan 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, Chief Financial Officer
    Poulton Jeffrey V.cik:0001782962
    Issuer
    ALNYLAM PHARMACEUTICALS, INC.cik:0001178670

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.